Dr. Andrew R. Bruggeman, MD

Dr. Bruggeman practices at Sharp Chula Vista Medical Center in Chula Vista, California, part of Sharp HealthCare.

Dr. Bruggeman's NPI, 1790049591, was assigned on June 27, 2012. Dr. Bruggeman graduated from Medical College of Ohio in 2012. Dr. Bruggeman holds California license A126549.

Dr. Bruggeman's primary practice is Sharp Chula Vista Medical Center, at 751 Medical Center Court, Chula Vista, CA 91911 in San Diego County. The practice phone is (619) 502-5800.

Dr. Bruggeman's primary practice is Sharp Chula Vista Medical Center in Chula Vista, California, part of Sharp HealthCare. Dr. Bruggeman is also affiliated with Sharp Grossmont Hospital. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Bruggeman to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bruggeman practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Bruggeman's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Bruggeman is board certified in radiation oncology by the American Board of Radiology. Dr. Bruggeman is licensed in California.

Dmand AI lists bone cancer radiation, brain cancer radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation and lymphoma radiation among the conditions Dr. Bruggeman treats.

CMS data shows 1,280 Medicare services from Dr. Bruggeman across 17 procedure codes in 2024, for 117 Medicare patients. Medicare paid $106,213 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 117 Medicare patients who saw Dr. Bruggeman in 2024. The largest group is 65 to 74, with 55 patients. 75% of them have cancer, and 75% have high blood pressure. 28% are also on Medicaid. Their average risk score is 1.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bruggeman's median patient age at 70, with 52% women.

In 2024, Dr. Bruggeman wrote 91 Medicare Part D claims for 50 patients. 98% of them were for generic drugs. CMS names the drug for 32 of them, across 2 drugs with 11 or more claims each, at $223 in total drug cost. In 2023, CMS named 16 claims across 1 drug.

Dr. Bruggeman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 15 papers to Dr. Bruggeman, published from 2015 to 2023. 2021 was the busiest year, with 5. The most frequent topics are Palliative Care, Radiation Oncology and Lung Neoplasms. Dr. Bruggeman has published most often in Ann Palliat Med. Dr. Bruggeman's most frequent co-authors are James Don Murphy, MD, Eric Roeland, MD and Reith R. Sarkar, MD.

CMS Open Payments shows 19 general payments to Dr. Bruggeman from 14 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. icotec Medical Inc. paid the most, $123.

Dmand AI lists 4 awards for Dr. Bruggeman, most recently Whitehill Award for Excellence in Teaching in 2021.

Dr. Bruggeman graduated from Medical College of Ohio in 2012. Dr. Bruggeman is a member of AMA, ASTRO, ASCO and CMA.

Dr. Bruggeman is in network with 16 carriers, including Elevance, Aetna and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.